First human test of new cancer drug begins
NCT ID NCT02275910
Summary
This was an early safety study of an experimental drug called E7090 for people with advanced solid tumors that had stopped responding to standard treatments. The study involved 40 participants and had two main goals: first, to find the highest safe dose of the drug, and second, to check for side effects and see if the drug showed any early signs of helping to control tumors, especially those with specific genetic changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Eisai Trial Site #1
Nagoya, Aichi-ken, Japan
-
Eisai Trial Site #1
Kashiwa, Chiba, Japan
-
Eisai Trial Site #1
Matsuyama, Ehime, Japan
-
Eisai Trial Site #1
Sapporo, Hokkaido, Japan
-
Eisai Trial Site #1
Amagasaki, Hyōgo, Japan
-
Eisai Trial Site #1
Tsukuba, Ibaraki, Japan
-
Eisai Trial Site #1
Kawasaki, Kanagawa, Japan
-
Eisai Trial Site #1
Yokohama, Kanagawa, Japan
-
Eisai Trial Site #1
Chuo-ku, Niigata, Japan
-
Eisai Trial Site #1
Kitaadachi, Saitama, Japan
-
Eisai Trial Site #1
Chuo-Ku, Tokyo, Japan
-
Eisai Trial Site #1
Koto-ku, Tokyo, Japan
-
Eisai Trial Site #1
Chiba, Japan
-
Eisai Trial Site #1
Fukuoka, Japan
-
Eisai Trial Site #1
Kyoto, Japan
-
Eisai Trial Site #1
Osaka, Japan
-
Eisai Trial Site #2
Osaka, Japan
-
Eisai Trial Site #3
Osaka, Japan
Conditions
Explore the condition pages connected to this study.